Valuation: Erasca, Inc.

Market Cap 6.43B 5.55B 5.22B 4.75B 8.92B 615B 9.07B 61.13B 23.9B 308B 24.14B 23.61B 1,023B P/E 2026 *
-18.8x
P/E 2027 * -30.4x
Enterprise Value 5.53B 4.78B 4.49B 4.09B 7.68B 529B 7.81B 52.63B 20.58B 265B 20.78B 20.33B 881B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
90.52%
Yield 2026 *
-
Yield 2027 * -
1 day+2.91%
1 week-0.16%
Current month+1.27%
1 month-13.55%
3 months+79.67%
6 months+53.17%
Current year+394.09%
1 week 17.3
Extreme 17.3
19.22
1 month 17.08
Extreme 17.08
19.96
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 2019-02-28
Director of Finance/CFO 43 2021-01-06
Chief Tech/Sci/R&D Officer - 2022-05-24
Director TitleAgeSince
Chairman 54 2018-09-30
Director/Board Member 79 2018-05-31
Director/Board Member 58 2018-07-01
Date Insider Type Main position Quantity % Market Cap.
8/10/26 Free

Chief Technology Officer

1,300,000 0.3745%
6/26/26 Free

Director

29,888 0.0096%
1/29/26 Free

General Counsel

560,000 0.1974%
Change 5-day change 1-year change 3-year change Capi.($)
+2.91%-0.16%+1,020.73%+622.20% 6.43B
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average -0.31%+0.42%+182.76%+167.32% 26.96B
Weighted average by Cap. -0.82%+0.57%+119.31%+145.37%

Financials

2026 *2027 *
Net sales - -
Net income -318M -275M -258M -235M -442M -30.45B -449M -3.03B -1.18B -15.25B -1.2B -1.17B -50.68B -208M -180M -169M -153M -289M -19.88B -293M -1.98B -773M -9.96B -781M -764M -33.08B
Net Debt -894M -772M -726M -660M -1.24B -85.51B -1.26B -8.5B -3.33B -42.82B -3.36B -3.28B -142B -740M -639M -600M -546M -1.03B -70.71B -1.04B -7.03B -2.75B -35.41B -2.78B -2.72B -118B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
26-08-14 US$18.38 +2.91% 2,465,955
26-08-13 US$17.86 -3.88% 2,604,948
26-08-12 US$18.58 +1.47% 3,647,530
26-08-11 US$18.31 +1.05% 3,426,210
26-08-10 US$18.12 -1.58% 3,896,855
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.38USD
Average target price
23.30USD
Spread / Average Target
+26.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock